Aspirin-Linked Reduction in CRC Risk Varies With Lifestyle Score
By Elana Gotkine HealthDay Reporter
TUESDAY, Aug. 6, 2024 -- Aspirin use is associated with a reduction in colorectal cancer (CRC) risk, with the greatest reduction seen among those with the unhealthiest lifestyle scores, according to a study published online Aug. 1 in JAMA Oncology.
Daniel R. Sikavi, M.D., from Massachusetts General Hospital and Harvard Medical School in Boston, and colleagues examined whether aspirin use is associated with the risk for CRC across different lifestyle risk factors in a prospective cohort study involving 63,957 women in the Nurses' Health Study (1980 to 2018) and 43,698 men in the Health Professionals Follow-Up Study (1986 to 2018).
The researchers identified 2,544 incident cases of CRC during 3,038,215 person-years of follow-up. The 10-year cumulative CRC incidence rates were 1.98 and 2.95 percent for those who regularly used aspirin and those who did not use aspirin, respectively, corresponding to an absolute risk reduction (ARR) of 0.97 percent. Those with the unhealthiest lifestyle scores had the greatest ARR associated with aspirin use, which decreased progressively with healthier lifestyle scores. For lifestyle scores of 0 to 1 (unhealthiest), the 10-year ARR was 1.28 percent compared with 0.11 percent for scores 4 to 5 (healthiest). The 10-year number needed to treat with aspirin was 78, 164, 154, and 909 for participants with lifestyle scores of 0 to 1, 2, 3, and 4 to 5, respectively. The greatest differences in ARR associated with aspirin use were seen for body mass index and smoking.
"These results support the use of lifestyle risk factors to identify individuals who may have a more favorable risk-benefit profile for cancer prevention with aspirin," the authors write.
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Multitarget Stool DNA Tests More Costly Than FIT for Colorectal Cancer Detection
WEDNESDAY, May 14, 2025 -- Multitarget stool DNA test (MSDT)- and next-generation MSDT (N-G MSDT)-based screening have higher costs per detected advanced neoplasia case or early...
Digestive Disease Week, May 3-6
Digestive Disease Week, the annual meeting sponsored by the American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society for...
Early-Life Exposure to Certain Bacteria May Impact Early-Onset Colorectal Cancer Incidence
TUESDAY, May 6, 2025 -- Early-life mutagenic exposure to colibactin-producing bacteria may be associated with the increased incidence of early-onset colorectal cancer, with...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.